The page presents Immusoft news, press releases, and publications on its engineered B cell therapies and progress across MPS I, MPS II, and rare diseases.
Julia Moore is a partner at Breakout Ventures, which invests in early-stage life sciences companies. Moore and her partners run Breakout Labs, a seed fund within Peter Thiel’s foundation focused on breakthrough technologies across hard sciences.
Matthew Scholz founded Immusoft and served as its CEO from 2009 through 2017. Scholz conceived how to modify a research system developed by Nobel laureate and former Caltech president David Baltimore to program resting B cells to secrete.
The page provides a contact option for inquiries about Immusoft’s engineered B cell therapies, research collaborations, partnership opportunities, and clinical programs.
Immusoft is pioneering engineered B cell therapies through Immune System Programming (ISP), turning a patient's own cells into biofactories for rare disease.